全身照射加足叶乙甙联合自体造血干细胞移植治疗非霍奇金淋巴 …

目的 评价全身照射（ＴＢＩ）加足叶乙甙（ＶＰ－１６）作为自体造血干细胞移植（ＡＨＳＣＴ）的预处理方法治疗非霍奇金淋巴瘤（ＮＨＬ）的疗效和安全性。方法 ２４例诱导治疗缓解的中高度恶性ＮＨＬ进行ＡＨＳＣＴ,其中２３例为首次缓解,１例为第３次缓解。自体骨髓移植（ＡＢＭＴ）１０例,自体外周血干细胞移植（ＡＰＢＳＣＴ）１４例,采用ＴＢＩ８００（７００－８５０）ｃＧｙ／Ｖｐ－１６７５７（２３－１１４０）ｍｇ／

Total body irradiation etoposide followed by autologous hematopoietic stem cell transplantion for non-Hodgkin's lymphoma

OBJECTIVE: To evaluate the therapeutic effectiveness and safety of total body irradiation(TBI) and Etoposide(Vp-16) as a preparative regimen for autologous hematopoietic stem cell transplantation(AHSCT) with non-Hodgkin's lymphoma(NHL). METHODS: Twenty-four patients with intermediate and high grade NHL underwent AHSCT. They achieved complete remission (CR) or partial remission (PR) after induction chemoradiotherapy. Twenty-three patients had first CR or PR, and one third CR. Ten patients underwent autologous bone marrow transplantation (ABMT) and 14 autologous peripheral blood stem cell transplantation (APBSCT). The preparative regimen was TBI 800(700-850) cGy/Vp-16 757(323-1140) mg/m2. RESULTS: At a median follow-up of 22.5(2-92) months, the one-year disease free survival(DFS) was 86.7% (13/15), 3-year, 5-year and 7-year DFS were 80.0% (12/15) in patients with CR before AHSCT. The DFS was 66.7% (4/6) in patients with PR before AHSCT. The patients who had relapsed before AHSCT(3 cases) did not reach DFS. The hematopoietic function recovery was rapid in APBSCT than ABMT. CONCLUSION: The clinical results of AHSCT for intermediate and high grade NHL who achieved CR or PR after induction therapy are satisfactory. The TBI/Etoposide is an effective and safe preparative regimen for AHSCT in NHL patients.